Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation–related genes analysis and identify potential therapeutic target ARFIP2

Hepatocellular carcinoma is one of the most common malignancies, and its prognosis and treatment outcome cannot be accurately predicted. ADP-ribosylation (ADPR) is a post-translationa modification of proteins involved in protein trafficking and immune response. Therefore, it is necessary to explore the ADPR-related genes associated with the prognosis and therapeutic efficacy of hepatocellular carcinoma treatments.